Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation.

1. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34-45.

2. Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost.

2020;46(1):89-95.

3. Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in

disseminated intravascular coagulation and other critical

conditions-a multi-faceted anticoagulant protein with therapeutic

potential. Crit Care. 2019;23(1):280.

4. Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care. 2006;10(1):209.

5. Mazzeffi M, Chow JH, Amoroso A, et al. Revisiting the protein C

pathway: an opportunity for adjunctive intervention in

COVID-19? Anesth Analg. 2020;131(3):690-693.

6. Ito T, Kakuuchi M, Maruyama I. Endotheliopathy in septic conditions: mechanistic insight into intravascular coagulation. Crit

Care. 2021;25(1):95.

7. Tagami T, Matsui H, Horiguchi H, et al. Antithrombin and mortality

in severe pneumonia patients with sepsis-associated disseminated

10

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

Clinical and Applied Thrombosis/Hemostasis

intravascular coagulation: an observational nationwide study. J

Thromb Haemost. 2014;12(9):1470-1479.

Tagami T, Matsui H, Horiguchi H, et al. Recombinant human soluble

thrombomodulin and mortality in severe pneumonia patients with

sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. 2015;13(1):31-40.

Umemura Y, Yamakawa K, Hayakawa M, et al. Concomitant

versus individual administration of antithrombin and thrombomodulin for sepsis-induced disseminated intravascular coagulation: a

nationwide Japanese registry study. Clin Appl Thromb Hemost.

2018;24(5):734-740.

Sawano H, Shigemitsu K, Yoshinaga Y, et al. Combination

therapy with antithrombin and recombinant human soluble thrombomodulin in patients with severe sepsis and disseminated intravascular coagulation. J Jpn Assoc Acute Med. 2013;24(3):119131. in Japanese].

Yasuda N, Goto K, Ohchi Y, et al. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination

therapy in patients with severe sepsis and disseminated intravascular coagulation. J Crit Care. 2016;36:29-34.

Iba T, Hagiwara A, Saitoh D, et al. Effects of combination therapy

using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation. Ann Intensive Care.

2017;7(1):110.

Levi M, van der Poll T. The role of natural anticoagulants in the

pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb

Hemost. 2008;34(5):459-468.

Ghimire S, Ravi S, Budhathoki R, et al. Current understanding and

future implications of sepsis-induced thrombocytopenia. Eur J

Haematol. 2021;106(3):301-305.

Hui P, Cook DJ, Lim W, et al. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011;139(2):271-278.

Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple

organ failure, and disseminated intravascular coagulation.

Compared patterns of antithrombin III, protein C, and protein S

deficiencies. Chest. 1992;101(3):816-823.

Pettilä V, Pentti J, Pettilä M, et al. Predictive value of antithrombin III

and serum C-reactive protein concentration in critically ill patients

with suspected sepsis. Crit Care Med. 2002;30(2):271-275.

Matsubara T, Yamakawa K, Umemura Y, et al. Significance of

plasma fibrinogen level and antithrombin activity in sepsis: a multicenter cohort study using a cubic spline model. Thromb Res.

2019;181:17-23.

Claushuis TA, van Vught LA, Scicluna BP, et al.

Thrombocytopenia is associated with a dysregulated host response

in critically ill sepsis patients. Blood. 2016;127(24):3062-3072.

Thiery-Antier N, Binquet C, Vinault S, et al. Is thrombocytopenia

an early prognostic marker in septic shock? Crit Care Med.

2016;44(4):764-772.

Zhou H, Li Z, Liang H, et al. Thrombocytopenia and platelet

count recovery in patients with sepsis-3: a retrospective observational

study. Platelets. 2021:1-9. doi: 10.1080/09537104.2021.1970124

22. Zhou Z, Feng T, Xie Y, et al. Prognosis and rescue therapy for

sepsis-related severe thrombocytopenia in critically ill patients.

Cytokine. 2020;136:155227.

23. Mimuro J, Takahashi H, Kitajima I, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res. 2013;131(5):

436-443.

24. Eguchi Y, Gando S, Ishikura H, et al. Post-marketing surveillance data

of thrombomodulin alfa: sub-analysis in patients with sepsis-induced

disseminated intravascular coagulation. J Intensive Care.

2014;2(1):30.

25. Arishima T, Ito T, Yasuda T, et al. Circulating activated

protein C levels are not increased in septic patients treated

with recombinant human soluble thrombomodulin. Thromb

J. 2018;16:24.

26. Iba T, Nakarai E, Takayama T, et al. Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care. 2009;13(6):

R203.

27. Asakura H, Ontachi Y, Mizutani T, et al. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular

coagulation. Eur J Haematol. 2001;67(3):170-175.

28. Ebina M, Fujino K, Inoue A, et al. Effects of serum albumin levels

on antithrombin supplementation outcomes among patients with

sepsis-associated coagulopathy: a retrospective study. Clin Med

Insights Blood Disord. 2019;12:1-6.

29. Tsirigotis P, Chondropoulos S, Frantzeskaki F, et al.

Thrombocytopenia in critically ill patients with severe sepsis/

septic shock: prognostic value and association with a distinct

serum cytokine profile. J Crit Care. 2016;32:9-15.

30. de Stoppelaar SF, van’t Veer C, Claushuis TA, et al.

Thrombocytopenia impairs host defense in gram-negative

pneumonia-derived sepsis in mice. Blood. 2014;124(25):37813790.

31. Chen Z, Zhang H, Qu M, et al. Review: the emerging role of neutrophil extracellular traps in sepsis and sepsis-associated thrombosis. Front Cell Infect Microbiol. 2021;11:653228.

32. Shimomura Y, Suga M, Kuriyama N, et al. Recombinant human

thrombomodulin inhibits neutrophil extracellular trap formation

in vitro. J Intensive Care. 2016;4:48.

33. Kato Y, Nishida O, Kuriyama N, et al. Effects of thrombomodulin in reducing lethality and suppressing neutrophil

extracellular trap formation in the lungs and liver in a

lipopolysaccharide-induced murine septic shock model. Int J

Mol Sci. 2021;22(9):4933.

34. Shrestha B, Ito T, Kakuuchi M, et al. Recombinant thrombomodulin suppresses histone-induced neutrophil extracellular trap formation. Front Immunol. 2019;10:2535.

35. Coppo P. Secondary thrombotic microangiopathies. Rev Med

Interne. 2017;38(11):731-736.

36. Guglielmetti G, Quaglia M, Sainaghi PP, et al. “War to the knife”

against thromboinflammation to protect endothelial function of

COVID-19 patients. Crit Care. 2020;24(1):365.

...